CoChat
Sign Up
Cited by 16Sarcoma Diagnosis and TreatmentAcute Lymphoblastic Leukemia researchChromatin Remodeling and Cancer

Management of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects

Open access
Pushpam, Deepam, Garg, Vikas, Ganguly, Sandip, Biswas, Bivas·2020·OncoTargets and Therapy
DOI 10.2147/ott.s193363PMC PMC7293381
Open this paper in CoChat — free accountOpen PDF

Abstract

Paediatric sarcomas are a heterogeneous group of disorders constituting bone sarcoma and various soft tissue sarcomas. Almost one-third of these presents with metastasis at baseline and another one-third recur after initial curative treatment. There is a huge unmet need in this cohort in terms of curative options and/or prolongation of survival. In this review, we have discussed the current treatment options, challenges and future strategies of managing relapsed/refractory paediatric sarcomas. Upfront risk-adapted treatment with multidisciplinary management remains the main strategy to prevent future recurrence or relapse of the disease. In the case of limited local and/or systemic relapse or late relapse, initial multimodality management can be administered. In treatment-refractory cases or where cure is not feasible, the treatment options are limited to novel therapeutics, immunotherapeutic approach, targeted therapies, and metronomic therapies. A better understanding of disease biology, mechanism of treatment refractoriness, identifications of driver mutation, the discovery of novel targeted therapies, cellular vaccine and adapted therapies should be explored in relapsed/refractory cases. Close national and international collaboration for translation research is needed to fulfil the unmet need.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ott.s193363

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 190

  1. [1]Biswas B, Rastogi S, Khan SA, et al. Hypoalbuminaemia is an independent predictor of poor outcome in metastatic Ewing’s sarcoma family of tumours: a single institutional experience of 150 cases treated with uniform chemotherapy protocol. Clin Oncol. 2014; 26(11): 722– 729. doi: 10.1016/j.clon.2014.05.006 24919857 · DOI
  2. [2]Iqbal N, Shukla NK, Deo SVS, et al. Prognostic factors affecting survival in metastatic soft tissue sarcoma: an analysis of 110 patients. Clin Transl Oncol. 2016; 18(3): 310– 316. doi: 10.1007/s12094-015-1369-9 26243399 · DOI
  3. [3]Anderson ME. Update on survival in osteosarcoma. Orthop Clin North Am. 2016; 47(1): 283– 292. doi: 10.1016/j.ocl.2015.08.022 26614941 · DOI · Paper page
  4. [4]Gelderblom H, Jinks RC, Sydes M, et al. Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. Eur J Cancer. 2011; 47(6): 895– 902. 21216138
  5. [5]Gaspar N, Hawkins DS, Dirksen U, et al. Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol. 2015; 33(27): 3036– 3046. doi: 10.1200/JCO.2014.59.5256 26304893 · DOI
  6. [6]Stahl M, Ranft A, Paulussen M, et al. Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer. 2011; 57(4): 549– 553. doi: 10.1002/pbc.23040 21442722 · DOI
  7. [8]Pappo AS, Anderson JR, Crist WM, et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the intergroup rhabdomyosarcoma study Group. J Clin Oncol. 1999; 17(11): 3487– 3493. doi: 10.1200/JCO.1999.17.11.3487 10550146 · DOI
  8. [9]Dantonello TM, Int-Veen C, Winkler P, et al. Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma. J Clin Oncol. 2008; 26(3): 406– 413. doi: 10.1200/JCO.2007.12.2382 18202417 · DOI
  9. [10]Chisholm JC, Marandet J, Rey A, et al. Prognostic factors after relapse in nonmetastatic rhabdomyosarcoma: a nomogram to better define patients who can be salvaged with further therapy. J Clin Oncol. 2011; 29(10): 1319– 1325. doi: 10.1200/JCO.2010.32.1984 21357778 · DOI
  10. [11]Sung L, Anderson JR, Donaldson SS, et al. Late events occurring five years or more after successful therapy for childhood rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Eur J CanceR. 1990. 2004; 40(12): 1878– 1885. 15288290
  11. [12]Mazzoleni S, Bisogno G, Garaventa A, et al. Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma. Cancer. 2005; 104(1): 183– 190. doi: 10.1002/cncr.21138 15895378 · DOI
  12. [13]Dasgupta R, Rodeberg D. Non-rhabdomyosarcoma. Semin Pediatr Surg. 2016; 25(5): 284– 289. doi: 10.1053/j.sempedsurg.2016.09.012 27955731 · DOI
  13. [14]Parida L, Fernandez-Pineda I, Uffman JK, et al. Clinical management of infantile fibrosarcoma: a retrospective single-institution review. Pediatr Surg Int. 2013; 29(7): 703– 708. doi: 10.1007/s00383-013-3326-4 23708972 PMC4825685 · DOI
  14. [15]Loh ML, Ahn P, Perez-Atayde AR, Gebhardt MC, Shamberger RC, Grier HE. Treatment of infantile fibrosarcoma with chemotherapy and surgery: results from the Dana-Farber Cancer Institute and Children’s Hospital, Boston. J Pediatr Hematol Oncol. 2002; 24(9): 722– 726. 12468912
  15. [16]Gibbs CP, Kukekov VG, Reith JD, et al. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia. 2005; 7(11): 967– 976. doi: 10.1593/neo.05394 16331882 PMC1502023 · DOI
  16. [17]Tirino V, Desiderio V, d’Aquino R, et al. Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One. 2008; 3(10): e3469. 18941626 PMC2565108
  17. [18]Adhikari AS, Agarwal N, Wood BM, et al. CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res. 2010; 70(11): 4602– 4612. doi: 10.1158/0008-5472.CAN-09-3463 20460510 PMC3139225 · DOI
  18. [19]Martins-Neves SR, Paiva-Oliveira DI, Wijers-Koster PM, et al. Chemotherapy induces stemness in osteosarcoma cells through activation of Wnt/β-catenin signaling. Cancer Lett. 2016; 370(2): 286– 295. doi: 10.1016/j.canlet.2015.11.013 26577806 · DOI
  19. [20]Tang Q-L, Liang Y, Xie X-B, et al. Enrichment of osteosarcoma stem cells by chemotherapy. Chin J Cancer. 2011; 30(6): 426– 432. doi: 10.5732/cjc.011.10127 21627865 PMC4013417 · DOI
  20. [22]Iwaya K, Ogawa H, Kuroda M, Izumi M, Ishida T, Mukai K. Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis. Clin Exp Metastasis. 2003; 20(6): 525– 529. doi: 10.1023/A:1025821229013 14598886 · DOI
  21. [23]Zhang F, Chen A, Chen J, Yu T, Guo F. siRNA-mediated silencing of beta-catenin suppresses invasion and chemosensitivity to doxorubicin in MG-63 osteosarcoma cells. Asian Pac J Cancer. 2011; 12(1): 239– 245. 21517265
  22. [24]Wu J, Liao Q, He H, Zhong D, Yin K. TWIST interacts with β-catenin signaling on osteosarcoma cell survival against cisplatin. Mol Carcinog. 2014; 53(6): 440– 446. doi: 10.1002/mc.21991 23280703 · DOI
  23. [25]Ma Y, Ren Y, Han EQ, et al. Inhibition of the Wnt-β-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy. Biochem Biophys Res Commun. 2013; 431(2): 274– 279. doi: 10.1016/j.bbrc.2012.12.118 23291185 PMC3710725 · DOI
  24. [26]Basu-Roy U, Basilico C, Mansukhani A. Perspectives on cancer stem cells in osteosarcoma. Cancer Lett. 2013; 338(1): 158– 167. doi: 10.1016/j.canlet.2012.05.028 22659734 PMC3552024 · DOI
  25. [27]Rajkumar T, Yamuna M. Multiple pathways are involved in drug resistance to doxorubicin in an osteosarcoma cell line. Anticancer Drugs. 2008; 19(3): 257– 265. doi: 10.1097/CAD.0b013e3282f435b6 18510171 · DOI
  26. [28]Baldini N, Scotlandi K, Barbanti-Bròdano G, et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med. 1995; 333(21): 1380– 1385. doi: 10.1056/NEJM199511233332103 7477118 · DOI
  27. [29]Windsor RE, Strauss SJ, Kallis C, Wood NE, Whelan JS. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study. Cancer. 2012; 118(7): 1856– 1867. doi: 10.1002/cncr.26472 21887680 · DOI
  28. [30]Ifergan I, Meller I, Issakov J, Assaraf YG. Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity. Cancer. 2003; 98(9): 1958– 1966. doi: 10.1002/cncr.11741 14584080 · DOI
  29. [31]Patiño-García A, Zalacaín M, Marrodán L, San-Julián M, Sierrasesúmaga L. Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression. J Pediatr. 2009; 154(5): 688– 693. doi: 10.1016/j.jpeds.2008.11.030 19159907 · DOI
  30. [32]Uozaki H, Horiuchi H, Ishida T, Iijima T, Imamura T, Machinami R. Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase π, heat shock protein 27, and lung resistance-related protein) in osteosarcoma. Cancer. 1997; 79(12): 2336– 2344. doi: 10.1002/(SICI)1097-0142(19970615)79:12<2336::AID-CNCR7>3.0.CO;2-J 9191521 · DOI
  31. [33]Wei L, Song X-R, Wang X-W, Li M, Zuo W-S. Expression of MDR1 and GST-pi in osteosarcoma and soft tissue sarcoma and their correlation with chemotherapy resistance. Zhonghua Zhong Liu Za Zhi. 2006; 28(6): 445– 448. 17152492
  32. [34]Biason P, Hattinger CM, Innocenti F, et al. Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy. Pharmacogenomics J. 2012; Dec;12(6): 476– 483. doi: 10.1038/tpj.2011.33 PMC3935514 21826087 · DOI
  33. [35]Caronia D, Patiño-García A, Milne RL, et al. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J. 2009; 9(5): 347– 353. doi: 10.1038/tpj.2009.19 19434073 · DOI
  34. [36]Li J, Liu S, Wang W, et al. ERCC polymorphisms and prognosis of patients with osteosarcoma. Tumour Biol. 2014; 35(10): 10129– 10136. doi: 10.1007/s13277-014-2322-1 25023406 · DOI
  35. [37]Yang J, Yang D, Cogdell D, et al. APEX1 gene amplification and its protein overexpression in osteosarcoma: correlation with recurrence, metastasis, and survival. Technol Cancer Res Treat. 2010; 9(2): 161– 169. doi: 10.1177/153303461000900205 20218738 · DOI
  36. [38]Chen R, Wang G, Zheng Y, Hua Y, Cai Z. Drug resistance‐related microRNAs in osteosarcoma: translating basic evidence into therapeutic strategies. J Cell Mol Med. 2019; 23(4): 2280– 2292. doi: 10.1111/jcmm.14064 30724027 PMC6433687 · DOI
  37. [39]Lin PP, Wang Y, Lozano G. Mesenchymal stem cells and the origin of Ewing’s sarcoma. Sarcoma. 2011; 2011. PMC2952797 20953407
  38. [40]Ahmed AA, Zia H, Wagner L. Therapy resistance mechanisms in Ewing’s sarcoma family tumors. Cancer Chemother Pharmacol. 2014; 73(4): 657– 663. doi: 10.1007/s00280-014-2392-1 24469502 · DOI
  39. [41]Scotlandi K, Remondini D, Castellani G, et al. Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome. J Clin Oncol. 2009; 27(13): 2209– 2216. doi: 10.1200/JCO.2008.19.2542 19307502 · DOI
  40. [42]Mendoza-Naranjo A, El-Naggar A, Wai DH, et al. ERBB4 confers metastatic capacity in Ewing sarcoma. EMBO Mol Med. 2013; 5(7): 1087– 1102. doi: 10.1002/emmm.201202343 23681745 PMC3721475 · DOI
  41. [43]Crompton BD, Stewart C, Taylor-Weiner A, et al. The genomic landscape of pediatric Ewing sarcoma. Cancer Discov. 2014; 4(11): 1326– 1341. doi: 10.1158/2159-8290.CD-13-1037 25186949 · DOI
  42. [44]Wu X, Xiao H, Wang R, Liu L, Li C, Lin J. Persistent GP130/STAT3 signaling contributes to the resistance of doxorubicin, cisplatin, and MEK inhibitor in human rhabdomyosarcoma cells. Curr Cancer Drug Targets. 2016; 16(7): 631– 638. doi: 10.2174/1568009615666150916093110 26373715 PMC5014400 · DOI
  43. [45]Citti A, Boldrini R, Inserra A, et al. Expression of multidrug resistance-associated proteins in paediatric soft tissue sarcomas before and after chemotherapy. Int J Oncol. 2012; 41(1): 117– 124. doi: 10.3892/ijo.2012.1433 22504834 · DOI
  44. [46]Schmid E, Stagno MJ, Yan J, et al. Serum and glucocorticoid inducible kinase 1-sensitive survival, proliferation and migration of rhabdomyosarcoma cells. Cell Physiol Biochem. 2017; 43(3): 1301– 1308. doi: 10.1159/000481842 28992614 · DOI
  45. [47]Seitz G, Bonin M, Fuchs J, et al. Inhibition of glutathione-S-transferase as a treatment strategy for multidrug resistance in childhood rhabdomyosarcoma. Int J Oncol. 2010; 36(2): 491– 500. 20043085
  46. [48]Bhuvaneshwar K, Harris M, Gusev Y, et al. Genome sequencing analysis of blood cells identifies germline haplotypes strongly associated with drug resistance in osteosarcoma patients. BMC Cancer. 2019; 19: 1. doi: 10.1186/s12885-019-5474-y 30991985 PMC6466653 · DOI
  47. [49]Chiappetta C, Mancini M, Lessi F, et al. Whole-exome analysis in osteosarcoma to identify a personalized therapy. Oncotarget. 2017; 8: 46. doi: 10.18632/oncotarget.19010 PMC5655208 29113313 · DOI
  48. [50]Subbiah V, Wagner MJ, McGuire MF, et al. Personalized comprehensive molecular profiling of high risk osteosarcoma: implications and limitations for precision medicine. Oncotarget. 2015; 6(38): 38. doi: 10.18632/oncotarget.5841 PMC4747358 26510912 · DOI
  49. [51]Chang W, Brohl AS, Patidar R, et al. MultiDimensional clinOmics for precision therapy of children and adolescent young adults with relapsed and refractory cancer: a report from the center for cancer research. Clin Cancer Res. 2016; 22(15): 3810– 3820. doi: 10.1158/1078-0432.CCR-15-2717 26994145 PMC4970946 · DOI
  50. [52]Worst BC, van Tilburg CM, Balasubramanian GP, et al. Next-generation personalised medicine for high-risk paediatric cancer patients – the INFORM pilot study. Eur J Cancer. 2016; 65: 91– 101. doi: 10.1016/j.ejca.2016.06.009 27479119 · DOI
  51. [53]Khater F, Vairy S, Langlois S, et al. Molecular profiling of hard-to-treat childhood and adolescent cancers. JAMA Netw Open. 2019; 2(4): e192906. doi: 10.1001/jamanetworkopen.2019.2906 31026031 PMC6487576 · DOI
  52. [54]Groisberg R, Hong DS, Holla V, et al. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget. 2017; 8: 24. doi: 10.18632/oncotarget.16845 PMC5503611 28424409 · DOI
  53. [55]Weidenbusch B, Richter GHS, Kesper MS, et al. Transcriptome based individualized therapy of refractory pediatric sarcomas: feasibility, tolerability and efficacy. Oncotarget. 2018; 9(29): 29. doi: 10.18632/oncotarget.25087 PMC5945512 29755686 · DOI
  54. [56]Suehara Y, Alex D, Bowman A, et al. Clinical genomic sequencing of pediatric and adult osteosarcoma reveals distinct molecular subsets with potentially targetable alterations. Clin Cancer Res. 2019; 25(21): 6346– 6356. doi: 10.1158/1078-0432.CCR-18-4032 31175097 PMC6825534 · DOI · Paper page
  55. [57]Yang J, Yang D, Sun Y, et al. Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. Cancer. 2011; 117(21): 4925– 4938. doi: 10.1002/cncr.26116 21495021 PMC3465081 · DOI
  56. [58]Hayes-Jordan A, Doherty DK, West SD, et al. Outcome after surgical resection of recurrent rhabdomyosarcoma. J Pediatr Surg. 2006; 41(4): 633– 638. doi: 10.1016/j.jpedsurg.2005.12.002 16567168 · DOI
  57. [59]De Corti F, Bisogno G, Dall’Igna P, et al. Does surgery have a role in the treatment of local relapses of non-metastatic rhabdomyosarcoma? Pediatr Blood Cancer. 2011; 57(7): 1261– 1265. doi: 10.1002/pbc.23225 21826783 · DOI
  58. [60]Angelini L, Bisogno G, Alaggio R, et al. Prognostic factors in children undergoing salvage surgery for bladder/prostate rhabdomyosarcoma. J Pediatr Urol. 2016; 12(4): 265.e1–8. doi: 10.1016/j.jpurol.2016.04.014 27255731 · DOI
  59. [61]Kung FH, Desai SJ, Dickerman JD, et al. Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II study. J Pediatr Hematol Oncol. 1995; 17(3): 265– 269. doi: 10.1097/00043426-199508000-00009 7620926 · DOI
  60. [62]Van Winkle P, Angiolillo A, Krailo M, et al. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children’s Cancer Group (CCG) experience. Pediatr Blood Cancer. 2005; 44(4): 338– 347. doi: 10.1002/pbc.20227 15503297 · DOI
  61. [63]Rl S, Kc S, J S J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a pediatric oncology group Phase II Study. J Clin Oncol. 2001. 11481351
  62. [64]Compostella A, Affinita MC, Casanova M, et al. Topotecan/carboplatin regimen for refractory/recurrent rhabdomyosarcoma in children: report from the AIEOP Soft Tissue Sarcoma Committee. Tumori. 2019; 105(2): 138– 143. doi: 10.1177/0300891618792479 30131003 · DOI
  63. [65]Mascarenhas L, Lyden ER, Breitfeld PP, et al. Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2010; 28(30): 4658– 4663. doi: 10.1200/JCO.2010.29.7390 20837952 PMC2974343 · DOI
  64. [66]Abstracts S. Pediatr blood cancer. 2019; 66(S4): e27989. 31568621
  65. [67]Weigel BJ, Breitfeld PP, Hawkins D, Crist WM, Baker KS. Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma. J Pediatr Hematol Oncol. 2001; 23(5): 272– 276. doi: 10.1097/00043426-200106000-00007 11464981 · DOI
  66. [68]Peinemann F, Kröger N, Bartel C, et al. High-dose chemotherapy followed by autologous stem cell transplantation for metastatic rhabdomyosarcoma–a systematic review. PLoS One. 2011; 6(2): e17127. doi: 10.1371/journal.pone.0017127 21373200 PMC3044147 · DOI
  67. [69]Rengaswamy V, Zimmer D, Süss R, Rössler J. RGD liposome-protamine-siRNA (LPR) nanoparticles targeting PAX3-FOXO1 for alveolar rhabdomyosarcoma therapy. J Controlled Release. 2016; 235: 319– 327. doi: 10.1016/j.jconrel.2016.05.063 27261335 · DOI
  68. [70]Gryder BE, Yohe ME, Chou H-C, et al. PAX3–FOXO1 establishes myogenic super enhancers and confers bet bromodomain vulnerability. Cancer Discov. 2017; 7(8): 884– 899. doi: 10.1158/2159-8290.CD-16-1297 28446439 PMC7802885 · DOI
  69. [71]Böhm M, Wachtel M, Marques JG, et al. Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma. J Clin Invest. 2016; 126(11): 4237– 4249. doi: 10.1172/JCI85057 27760049 PMC5096911 · DOI
  70. [72]Chen C, Dorado Garcia H, Scheer M, Henssen AG. Current and future treatment strategies for rhabdomyosarcoma. Front Oncol. 2019; 20;9(20): 1903– 1904. doi: 10.1016/0006-2952(75)90415-3 PMC6933601 31921698 · DOI
  71. [73]Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med. 1999; 341(5): 342– 352. doi: 10.1056/NEJM199907293410507 10423470 · DOI · Paper page
  72. [74]Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986; 314(25): 1600– 1606. doi: 10.1056/NEJM198606193142502 3520317 · DOI
  73. [75]Gelderblom H, Jinks RC, Sydes M, et al. Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. Eur J Cancer. 2011; 47(6): 895– 902. 21216138
  74. [76]Kempf-Bielack B, Bielack SS, Jürgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol. 2005; 23(3): 559– 568. doi: 10.1200/JCO.2005.04.063 15659502 · DOI · Paper page
  75. [77]Ferrari S, Briccoli A, Mercuri M, et al. Late relapse in osteosarcoma. J Pediatr Hematol Oncol. 2006; 28(7): 418– 422. doi: 10.1097/01.mph.0000212944.82361.1d 16825986 · DOI
  76. [78]Bacci G, Forni C, Longhi A, et al. Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. J Surg Oncol. 2007; 96(2): 118– 123. doi: 10.1002/jso.20628 17577221 · DOI
  77. [79]Bacci G, Ferrari S, Lari S, et al. Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy. J Bone Joint Surg Br. 2002; 84(1): 88– 92. 11837839
  78. [80]Grimer RJ, Sommerville S, Warnock D, et al. Management and outcome after local recurrence of osteosarcoma. Eur J Cancer. 2005; 41(4): 578– 583. doi: 10.1016/j.ejca.2004.11.012 15737563 · DOI
  79. [81]Nathan SS, Gorlick R, Bukata S, et al. Treatment algorithm for locally recurrent osteosarcoma based on local disease-free interval and the presence of lung metastasis. Cancer. 2006; 107(7): 1607– 1616. doi: 10.1002/cncr.22197 16933325 · DOI
  80. [82]Bacci G, Briccoli A, Longhi A, et al. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol Stockh Swed. 2005; 44(7): 748– 755. doi: 10.1080/02841860500327503 16227167 · DOI · Paper page
  81. [83]Palmerini E, Torricelli E, Cascinu S, et al. Is there a role for chemotherapy after local relapse in high-grade osteosarcoma? Pediatr Blood Cancer. 2019; 66(8): e27792. doi: 10.1002/pbc.27792 31058424 · DOI
  82. [84]Harting MT, Blakely ML. Management of osteosarcoma pulmonary metastases. Semin Pediatr Surg. 2006; 15(1): 25– 29. doi: 10.1053/j.sempedsurg.2005.11.005 16458843 · DOI
  83. [85]Chou AJ, Merola PR, Wexler LH, et al. Treatment of osteosarcoma at first recurrence after contemporary therapy: the memorial sloan-kettering cancer center experience. Cancer. 2005; 104(10): 2214– 2221. doi: 10.1002/cncr.21417 16206297 · DOI
  84. [86]Tabone MD, Kalifa C, Rodary C, Raquin M, Valteau-Couanet D, Lemerle J. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy.. J Clin Oncol. 1994; 12(12): 2614– 2620. doi: 10.1200/JCO.1994.12.12.2614 7989936 · DOI
  85. [87]Bielack SS, Kempf-Bielack B, Branscheid D, et al. Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol. 2009; 27(4): 557– 565. doi: 10.1200/JCO.2008.16.2305 19075282 · DOI · Paper page
  86. [88]Briccoli A, Rocca M, Salone M, Guzzardella GA, Balladelli A, Bacci G. High grade osteosarcoma of the extremities metastatic to the lung: long-term results in 323 patients treated combining surgery and chemotherapy, 1985–2005. Surg Oncol. 2010; 19(4): 193– 199. doi: 10.1016/j.suronc.2009.05.002 19515554 · DOI
  87. [89]Duffaud F, Digue L, Mercier C, et al. Recurrences following primary osteosarcoma in adolescents and adults previously treated with chemotherapy. Eur J Cancer. 2003; 39(14): 2050– 2057. doi: 10.1016/S0959-8049(03)00435-0 12957460 · DOI
  88. [90]Hawkins DS, Arndt CAS. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer. 2003; 98(11): 2447– 2456. doi: 10.1002/cncr.11799 14635080 · DOI · Paper page
  89. [91]de Baere T, Tselikas L, Gravel G, et al. Interventional radiology: role in the treatment of sarcomas. Eur J Cance. 2018; 94: 148– 155. doi: 10.1016/j.ejca.2018.02.017 29567631 · DOI
  90. [92]Yu W, Liu Z, Tang L, Lin F, Yao Y, Shen Z. Efficacy and safety of stereotactic radiosurgery for pulmonary metastases from osteosarcoma: experience in 73 patients. Sci Rep. 2017; 7(1): 17480. doi: 10.1038/s41598-017-14521-7 29234040 PMC5727072 · DOI
  91. [93]Bacci G, Longhi A, Bertoni F, et al. Bone metastases in osteosarcoma patients treated with neoadjuvant or adjuvant chemotherapy: the Rizzoli experience in 52 patients. Acta Orthop. 2006; 77(6): 938– 943. doi: 10.1080/17453670610013268 17260205 · DOI
  92. [94]Franke M, Hardes J, Helmke K, et al. Solitary skeletal osteosarcoma recurrence. Findings from the Cooperative Osteosarcoma Study Group. Pediatr Blood Cancer. 2011; 56(5): 771– 776. 21370409
  93. [95]Anderson PM, Wiseman GA, Dispenzieri A, et al. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol. 2002; 20(1): 189– 196. doi: 10.1200/JCO.2002.20.1.189 11773169 · DOI
  94. [96]Loeb DM, Garrett-Mayer E, Hobbs RF, et al. Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma. Cancer. 2009; 115(11): 2514– 2522. doi: 10.1002/cncr.24286 19338063 PMC2974628 · DOI
  95. [97]Subbiah V, Anderson P, Rohren E. Alpha emitter radium 223 in high-risk osteosarcoma: first clinical evidence of response and blood-brain barrier penetration. JAMA Oncol. 2015; 1(2): 253– 255. doi: 10.1001/jamaoncol.2014.289 26181034 · DOI
  96. [98]Anderson PM, Subbiah V, Rohren E. Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223. Adv Exp Med Biol. 2014; 804: 291– 304. 24924181
  97. [99]Harris MB, Cantor AB, Goorin AM, et al. Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. Med Pediatr Oncol. 1995; 24(2): 87– 92. doi: 10.1002/mpo.2950240205 7990769 · DOI
  98. [100]Gentet JC, Brunat-Mentigny M, Demaille MC, et al. Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. Eur J Cancer. 1997; 33(2): 232– 237. 9135494
  99. [101]Lee JA, Jeon D-G, Cho WH, et al. Higher gemcitabine dose was associated with better outcome of osteosarcoma patients receiving gemcitabine-docetaxel chemotherapy. Pediatr Blood Cancer. 2016; 63(9): 1552– 1556. doi: 10.1002/pbc.26058 27197055 · DOI · Paper page
  100. [102]Fox E, Patel S, Wathen JK, et al. Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. Oncologist. 2012; 17(3): 321. doi: 10.1634/theoncologist.2010-0265 22363068 PMC3316916 · DOI
  101. [103]Berger M, Massimo B, Grignani G, et al. Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients. Cancer. 2009; 115(13): 2980– 2987. doi: 10.1002/cncr.24368 19452540 · DOI
  102. [105]Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol. 2012; 23(2): 508– 516. doi: 10.1093/annonc/mdr151 21527590 · DOI · Paper page
  103. [106]Grignani G, Palmerini E, Ferraresi V, et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol. 2015; 16(1): 98– 107. doi: 10.1016/S1470-2045(14)71136-2 25498219 · DOI
  104. [109]Lashkari A, Chow WA, Valdes F, et al. Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma. Anticancer Res. 2009; 29(8): 3281– 3288. 19661346
  105. [110]Fagioli F, Aglietta M, Tienghi A, et al. High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. J Clin Oncol. 2002; 20(8): 2150– 2156. 11956277
  106. [112]Arndt CAS, Koshkina NV, Inwards CY, et al. Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children’s Oncology Group. Clin Cancer Res. 2010; 16(15): 4024– 4030. 20576718 PMC2989183
  107. [114]Leavey PJ, Mascarenhas L, Marina N, et al. Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children’s Oncology Group. Pediatr Blood Cancer. 2008; 51(3): 334– 338. doi: 10.1002/pbc.21618 18506764 PMC2728357 · DOI
  108. [115]Bacci G, Longhi A, Ferrari S, et al. Pattern of relapse in 290 patients with nonmetastatic Ewing’s sarcoma family tumors treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999. Eur J Surg Oncol. 2006; 32(9): 974– 979. doi: 10.1016/j.ejso.2006.01.023 16621429 · DOI
  109. [116]Wasilewski-Masker K, Liu Q, Yasui Y, et al. Late Recurrence in Pediatric Cancer: A Report From the Childhood Cancer Survivor Study. JNCI J Natl Cancer Inst. 2009; 101(24): 1709– 1720. doi: 10.1093/jnci/djp417 19966206 PMC2800799 · DOI
  110. [117]Heinemann M, Ranft A, Langer T, et al. Recurrence of Ewing sarcoma: is detection by imaging follow-up protocol associated with survival advantage? Pediatr Blood Cancer. 2018; 65(7): e27011. doi: 10.1002/pbc.27011 29480574 · DOI
  111. [118]Rodriguez-Galindo C, Billups CA, Kun LE, et al. Survival after recurrence of Ewing tumors: the St Jude Children’s Research Hospital experience, 1979-1999. Cancer. 2002; 94(2): 561– 569. doi: 10.1002/cncr.10192 11900241 · DOI
  112. [119]Wagner LM, McAllister N, Goldsby RE, et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer. 2007; 48(2): 132– 139. doi: 10.1002/pbc.20697 16317751 · DOI
  113. [120]Saylors RL, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol. 2001; 19(15): 3463– 3469. doi: 10.1200/JCO.2001.19.15.3463 11481351 · DOI
  114. [121]Kebudi R, Cakir FB, Gorgun O, Agaoglu FY, Darendeliler E. A modified protocol with vincristine, topotecan, and cyclophosphamide for recurrent/progressive Ewing sarcoma family tumors. Pediatr Hematol Oncol. 2013; 30(3): 170– 177. doi: 10.3109/08880018.2013.767868 23484903 · DOI
  115. [122]Tanaka K, Joyama S, Chuman H, et al. Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients. World J Surg Oncol. 2016; 14: 306. doi: 10.1186/s12957-016-1059-2 27931230 PMC5146834 · DOI
  116. [123]Ferrari S, Del Prever AB, Palmerini E, et al. Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma. Pediatr Blood Cancer. 2009; 52(5): 581– 584. doi: 10.1002/pbc.21917 19142994 · DOI
  117. [124]Palmerini E, Jones RL, Setola E, et al. Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients. Acta Oncol Stockh Swed. 2018; 57(7): 958– 964. doi: 10.1080/0284186X.2018.1449250 29533113 · DOI
  118. [125]Devadas SK, Banavali S. Retrospective analysis of outcomes of patients with relapsed, refractory and metastatic sarcomas who have received metronomic chemotherapy. Gulf J Oncolog. 2019; 1(30): 22– 28. 31242978
  119. [126]Kolb EA, Gorlick R. Development of IGF-IR inhibitors in pediatric sarcomas. Curr Oncol Rep. 2009; 11(4): 307– 313. doi: 10.1007/s11912-009-0043-1 19508836 · DOI
  120. [127]Richter GHS, Fasan A, Hauer K, et al. G-Protein coupled receptor 64 promotes invasiveness and metastasis in Ewing sarcomas through PGF and MMP1. J Pathol. 2013; 230(1): 70– 81. doi: 10.1002/path.4170 23338946 · DOI
  121. [128]Attia S, Bolejack V, Ganjoo KN, et al. A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results. J Clin Oncol. 2017; 35(15_suppl): 11005. doi: 10.1200/JCO.2017.35.15_suppl.11005 PMC9883574 35950293 · DOI
  122. [130]van Maldegem AM, JVMG B, Peterse EFP, Hogendoorn PCW, Gelderblom H. Ewing sarcoma: the clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway. Eur J Cancer. 2016; 53: 171– 180. doi: 10.1016/j.ejca.2015.09.009 26765686 · DOI
  123. [131]Zöllner SK, Selvanathan SP, Graham GT, et al. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G2-M cell cycle arrest and enhanced vincristine sensitivity in Ewing’s sarcoma. Sci Signal. 2017; 10: 499. doi: 10.1126/scisignal.aam8429 PMC7330879 28974650 · DOI
  124. [132]Gollavilli PN, Pawar A, Wilder-Romans K, et al. EWS/ETS-driven Ewing sarcoma requires BET bromodomain proteins. Cancer Res. 2018; 78(16): 4760– 4773. doi: 10.1158/0008-5472.CAN-18-0484 29898995 · DOI
  125. [133]Theisen ER, Pishas KI, Saund RS, Lessnick SL. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting. Oncotarget. 2016; 7(14): 17616– 17630. doi: 10.18632/oncotarget.7124 26848860 PMC4951237 · DOI
  126. [134]Pappo AS, Patel SR, Crowley J, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol. 2011; 29(34): 4541– 4547. doi: 10.1200/JCO.2010.34.0000 22025149 PMC3236654 · DOI
  127. [135]Malempati S, Weigel B, Ingle AM, et al. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2012; 30(3): 256– 262. doi: 10.1200/JCO.2011.37.4355 22184397 PMC3269952 · DOI
  128. [136]Tap WD, Demetri G, Barnette P, et al. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol. 2012; 30(15): 1849– 1856. doi: 10.1200/JCO.2011.37.2359 22508822 · DOI
  129. [137]Wagner LM, Fouladi M, Ahmed A, et al. Phase II Study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the children’s oncology group. Pediatr Blood Cancer. 2015; 62(3): 440– 444. doi: 10.1002/pbc.25334 25446280 PMC4501773 · DOI
  130. [138]Choy E, Butrynski JE, Harmon DC, et al. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer. 2014; 5(14): 813. doi: 10.1186/1471-2407-14-813 PMC4230717 25374341 · DOI
  131. [139]Ghisoli M, Barve M, Schneider R, et al. Pilot trial of FANG immunotherapy in Ewing’s sarcoma. Mol Ther. 2015; 23(6): 1103– 1109. doi: 10.1038/mt.2015.43 25917459 PMC4817748 · DOI
  132. [140]Gargallo P, Juan A, Yáñez Y, et al. Precision medicine in Ewing sarcoma: a translational point of view. Clin Transl Oncol. 2020. doi: 10.1007/s12094-020-02298-7 32026343 · DOI
  133. [141]Machado I, López-Guerrero JA, Scotlandi K, Picci P, Llombart-Bosch A. Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing’s sarcoma family of tumors (ESFT). Virchows Arch. 2018; 472(5): 815– 824. doi: 10.1007/s00428-018-2316-2 29445891 · DOI
  134. [142]Van Mater D, Wagner L. Management of recurrent Ewing sarcoma: challenges and approaches. OncoTargets Ther. 2019; 27(12): 2279– 2288. doi: 10.2147/OTT.S170585 PMC6441548 30988632 · DOI
  135. [143]Rao DD, Jay C, Wang Z, et al. Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing’s Sarcoma. Mol Ther. 2016; 24(8): 1412– 1422. doi: 10.1038/mt.2016.93 27166877 PMC5023384 · DOI
  136. [144]Ghisoli M, Barve M, Mennel R, et al. Three-year follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in metastatic advanced ewing’s sarcoma. Mol Ther. 2016; 24(8): 1478– 1483. doi: 10.1038/mt.2016.86 27109631 PMC5023386 · DOI
  137. [145]Rasper M, Jabar S, Ranft A, Jürgens H, Amler S, Dirksen U. The value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma. Pediatr Blood Cancer. 2014; 61(8): 1382– 1386. doi: 10.1002/pbc.25042 24729428 · DOI
  138. [146]Barker LM, Pendergrass TW, Sanders JE, Hawkins DS. Survival after recurrence of Ewing’s sarcoma family of tumors. J Clin Oncol. 2005; 23(19): 4354– 4362. doi: 10.1200/JCO.2005.05.105 15781881 · DOI
  139. [147]McTiernan A, Driver D, Michelagnoli MP, Kilby AM, Whelan JS. High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing’s sarcoma family of tumours. Ann Oncol. 2006; 17(8): 1301– 1305. doi: 10.1093/annonc/mdl108 16782749 · DOI
  140. [148]Hayani A, Mahoney DH, Hawkins HK, Steuber CP, Hurwitz R, Fernbach DJ. Soft-tissue sarcomas other than rhabdomyosarcoma in children. Med Pediatr Oncol. 1992; 20(2): 114– 118. doi: 10.1002/mpo.2950200205 1734215 · DOI
  141. [149]Orbach D, Rey A, Oberlin O, et al. Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee. J Clin Oncol. 2005; 23(19): 4363– 4371. 15994146
  142. [150]Coffin CM, Dehner LP. Soft tissue tumors in first year of life: a report of 190 cases. Pediatr Pathol. 1990; 10(4): 509– 526. doi: 10.3109/15513819009067140 2164660 · DOI
  143. [151]Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PH. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet. 1998; 18(2): 184– 187. doi: 10.1038/ng0298-184 9462753 · DOI
  144. [152]Orbach D, Rey A, Cecchetto G, et al. Infantile fibrosarcoma: management based on the European experience. J Clin Oncol. 2010; 28(2): 318– 323. doi: 10.1200/JCO.2009.21.9972 19917847 · DOI
  145. [153]Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018; 378(8): 731– 739. doi: 10.1056/NEJMoa1714448 29466156 PMC5857389 · DOI · Paper page
  146. [154]André N, Carré M, Pasquier E. Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol. 2014; 11(7): 413– 431. doi: 10.1038/nrclinonc.2014.89 24913374 · DOI
  147. [155]Porkholm M, Toiviainen-Salo S, Seuri R, et al. Metronomic therapy can increase quality of life during paediatric palliative cancer care, but careful patient selection is essential. Acta Paediatr. 2016; 105(8): 946– 951. doi: 10.1111/apa.13338 26801815 · DOI
  148. [156]André N, Abed S, Orbach D, et al. Pilot study of a pediatric metronomic 4-drug regimen. Oncotarget. 2011; 2(12): 960– 965. doi: 10.18632/oncotarget.358 22156656 PMC3282100 · DOI
  149. [157]Pramanik R, Agarwala S, Gupta YK, et al. Metronomic chemotherapy vs best supportive care in progressive pediatric solid malignant tumors: a randomized clinical trial. JAMA. 2017; 3(9): 1222. PMC5824286 28384657
  150. [158]Bonneville R, Krook MA, Kautto EA, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. 2017; 2017. PMC5972025 29850653
  151. [159]Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020; 38(1): 1– 10. doi: 10.1200/JCO.19.02105 31682550 PMC8184060 · DOI
  152. [160]Kim JR, Moon YJ, Kwon KS, et al. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One. 2013; 8(12): e82870. doi: 10.1371/journal.pone.0082870 24349382 PMC3859621 · DOI
  153. [161]Merchant MS, Wright M, Baird K, et al. Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors. Clin Cancer Res. 2016; 22(6): 1364– 1370. doi: 10.1158/1078-0432.CCR-15-0491 26534966 PMC5027962 · DOI · Paper page
  154. [162]Groisberg R, Hong DS, Behrang A, et al. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer. 2017; 5(1): 100. doi: 10.1186/s40425-017-0301-y 29254498 PMC5735899 · DOI
  155. [163]Davis KL, Fox E, Reid JM, et al. ADVL1412: initial results of a phase I/II study of nivolumab and ipilimumab in pediatric patients with relapsed/refractory solid tumors—A COG study. J Clin Oncol. 2017; 35(15_suppl): 10526. doi: 10.1200/JCO.2017.35.15_suppl.10526 · DOI
  156. [164]Merchant MS, Bernstein D, Amoako M, et al. Adjuvant immunotherapy to improve outcome in high-risk pediatric sarcomas. Clin Cancer Res. 2016; 22(13): 3182– 3191. doi: 10.1158/1078-0432.CCR-15-2550 26823601 PMC7831150 · DOI
  157. [165]Folkert IW, Devalaraja S, Linette GP, Weber K, Haldar M. Primary bone tumors: challenges and opportunities for CAR‐T therapies. J Bone Miner Res. 2019; 34(10): 1780– 1788. doi: 10.1002/jbmr.3852 31441962 · DOI
  158. [166]Zhu H, Gu S, Yin M, et al. Analysis of infantile fibrosarcoma reveals extensive T-cell responses within tumors: implications for immunotherapy. Pediatr Blood Cancer. 2018; 65(2): e26813. doi: 10.1002/pbc.26813 28921877 · DOI
  159. [167]Chang T-C, Carter RA, Li Y, et al. The neoepitope landscape in pediatric cancers. Genome Med. 2017; 9(1): 78. doi: 10.1186/s13073-017-0468-3 28854978 PMC5577668 · DOI
  160. [168]Pilbeam K, Wang H, Taras E, et al. Targeting pediatric sarcoma with a bispecific ligand immunotoxin targeting urokinase and epidermal growth factor receptors. Oncotarget. 2017; 9(15): 11938– 11947. doi: 10.18632/oncotarget.21187 29552283 PMC5844719 · DOI
  161. [169]Sp D, Mr M, Ba VT, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, Phase 2 Trials. Lancet Oncol. 2018. PMC6126546 29370992
  162. [170]Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018; 378(22): 2078– 2092. doi: 10.1056/NEJMoa1801005 29658856 · DOI · Paper page
  163. [171]Geiger JD, Hutchinson RJ, Hohenkirk LF, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 2001; 61(23): 8513– 8519. 11731436
  164. [172]Ahmed N, Brawley VS, Hegde M, et al. Human Epidermal Growth Factor Receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol. 2015; 33(15): 1688– 1696. doi: 10.1200/JCO.2014.58.0225 25800760 PMC4429176 · DOI · Paper page
  165. [173]Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018; 13;379(24): 2342– 2350. doi: 10.1056/NEJMoa1809697 30280658 · DOI · Paper page
  166. [174]Klingebiel T, Pertl U, Hess CF, et al. Treatment of children with relapsed soft tissue sarcoma: report of the German CESS/CWS REZ 91 trial. Med Pediatr Oncol. 1998; 30(5): 269– 275. doi: 10.1002/(SICI)1096-911X(199805)30:5<269::AID-MPO2>3.0.CO;2-D 9544222 · DOI
  167. [175]Defachelles AS, Bogart E, Casanova M, et al. Randomized phase 2 trial of the combination of vincristine and irinotecan with or without temozolomide, in children and adults with refractory or relapsed rhabdomyosarcoma (RMS). J Clin Oncol. 2019; 37(15_suppl): 10000. doi: 10.1200/JCO.2019.37.15_suppl.10000 · DOI
  168. [176]Setty BA, Stanek JR, Mascarenhas L, et al. VIncristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma. Pediatr Blood Cancer. 2018; 65(1): e26728. doi: 10.1002/pbc.26728 PMC7497851 28748602 · DOI
  169. [177]Kuttesch JF, Krailo MD, Madden T, Johansen M, Bleyer A. Children’s Oncology Group. Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children’s Oncology Group study. Pediatr Blood Cancer. 2009; 53(4): 590– 593. doi: 10.1002/pbc.22133 19533657 PMC2754403 · DOI
  170. [178]Casanova M, Ferrari A, Spreafico F, et al. Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma. Cancer. 2002; 94(12): 3263– 3268. doi: 10.1002/cncr.10600 12115359 · DOI
  171. [179]Casanova M, Ferrari A, Bisogno G, et al. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol. Cancer. 2004; 101(7): 1664– 1671. doi: 10.1002/cncr.20544 15378498 · DOI
  172. [180]Minard-Colin V, Ichante J-L, Nguyen L, et al. Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: good tolerance profile and efficacy in rhabdomyosarcoma–a report from the Société Française des Cancers et leucémies de l’Enfant et de l’adolescent (SFCE). Eur J Cancer Oxf Engl 1990. 2012; 48(15): 2409– 2416. 22633624
  173. [181]Mascarenhas L, Meyer WH, Lyden E, et al. Randomized phase II trial of bevacizumab and temsirolimus in combination with vinorelbine (V) and cyclophosphamide (C) for first relapse/disease progression of rhabdomyosarcoma (RMS): A report from the Children’s Oncology Group (COG). J Clin Oncol. 2014; 32(15_suppl): 10003. doi: 10.1200/jco.2014.32.15_suppl.10003 · DOI
  174. [182]Rapkin L, Qayed M, Brill P, et al. Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas. Pediatr Blood Cancer. 2012; 59(5): 854– 858. doi: 10.1002/pbc.24101 22302783 · DOI
  175. [183]Kung FH, Pratt CB, Vega RA, et al. Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study. Cancer. 1993; 71(5): 1898– 1903. doi: 10.1002/1097-0142(19930301)71:5<1898::AID-CNCR2820710529>3.0.CO;2-Q 8448755 · DOI
  176. [184]Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol off J Am Soc Clin Oncol. 1987; 5(8): 1191– 1198. doi: 10.1200/JCO.1987.5.8.1191 3114435 · DOI · Paper page
  177. [185]Cairo MS, Shen V, Krailo MD, et al. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children’s cancer group report. J Pediatr Hematol Oncol. 2001; 23(1): 30– 38. doi: 10.1097/00043426-200101000-00008 11196267 · DOI
  178. [186]Berrak SG, Pearson M, Berberoğlu S, Ilhan IE, Jaffe N. High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. Pediatr Blood Cancer. 2005; 44(3): 215– 219. doi: 10.1002/pbc.20228 15503294 · DOI
  179. [187]Navid F, Willert JR, McCarville MB, et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer. 2008; 113(2): 419– 425. doi: 10.1002/cncr.23586 18484657 · DOI
  180. [188]Qi W-X, He A-N, Tang L-N, Shen Z, Lin F, Yao Y. Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients. Jpn J Clin Oncol. 2012; 42(5): 427– 431. doi: 10.1093/jjco/hys030 22450929 · DOI
  181. [190]Anderson P, Kopp L, Anderson N, et al. Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing’s sarcoma and osteosarcoma). Expert Opin Investig Drugs. 2008; 17(11): 1703– 1715. doi: 10.1517/13543784.17.11.1703 18922107 · DOI
  182. [191]Casey DA, Wexler LH, Merchant MS, et al. Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer. 2009; 53(6): 1029– 1034. doi: 10.1002/pbc.22206 19637327 · DOI
  183. [192]Hernández-Marqués C, Lassaletta-Atienza A, Ruiz Hernández A, et al. [Irinotecan plus temozolomide in refractory or relapsed pediatric solid tumors]. An Pediatr Barc Spain. 2013; 79(2): 68– 74. Spanish. 23332825
  184. [193]Raciborska A, Bilska K, Drabko K, et al. Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma. Pediatr Blood Cancer. 2013; 60(10): 1621– 1625. doi: 10.1002/pbc.24621 23776128 · DOI
  185. [194]Kurucu N, Sari N, Ilhan IE. Irinotecan and temozolomide treatment for relapsed Ewing sarcoma: a single-center experience and review of the literature. Pediatr Hematol Oncol. 2015; 32(1): 50– 59. doi: 10.3109/08880018.2014.954070 25252096 · DOI
  186. [195]Büyükkapu Bay S, Kebudi R, Görgün O, Zülfikar B, Darendeliler E, Çakır FB. Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience. J Oncol Pharm Pract off Publ Int Soc Oncol Pharm Pract. 2019; 25(6): 1343– 1348. doi: 10.1177/1078155218790798 30080131 · DOI
  187. [196]Hunold A, Weddeling N, Paulussen M, Ranft A, Liebscher C, Jürgens H. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer. 2006; 47(6): 795– 800. doi: 10.1002/pbc.20719 16411206 · DOI
  188. [197]Farhat R, Raad R, Khoury NJ, et al. Cyclophosphamide and topotecan as first-line salvage therapy in patients with relapsed ewing sarcoma at a single institution. J Pediatr Hematol Oncol. 2013; 35(5): 356– 360. doi: 10.1097/MPH.0b013e318270a343 23042020 · DOI
  189. [198]Mora J, Cruz CO, Parareda A, de Torres C. Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel. J Pediatr Hematol Oncol. 2009; 31(10): 723– 729. doi: 10.1097/MPH.0b013e3181b2598c 19727011 · DOI
  190. [199]van Maldegem AM, Benson C, Rutkowski P, et al. Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study. Pediatr Blood Cancer. 2015; 62(1): 40– 44. doi: 10.1002/pbc.25230 25251256 · DOI

Cited by

Sorted by citations

Authors
Pushpam, D., Garg, V., Ganguly, S., & Biswas, B.
Affiliations
  • All India Institute of Medical Sciences (IN)
  • Tata Medical Center (IN)
Corresponding author
Biswas, Bivas
ORCID
Venue
OncoTargets and Therapy
Publisher
Informa UK Limited
Published
2020-06
Volume
Volume 13
Pages
5093-5112
ISSN
1178-6930 (ISSN-L)
DOI
10.2147/ott.s193363
PMC
PMC7293381
OpenAlex
W3033206180
Cited by
16
References
7
Citations by year
2026: 7 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 2 · 2020: 2
FWCI
0.25
Type
journal article
Language
en
Open access
Licence
Locations
  • OncoTargets and Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoma Diagnosis and Treatment
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Acute Lymphoblastic Leukemia research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords
pediatric sarcoma, refractory sarcoma, relapsed sarcoma, bone sarcoma, soft tissue sarcoma, risk-adapted treatment, multimodality management, immunotherapy, targeted therapy, driver mutations, cellular vaccine, treatment resistance mechanisms, unmet medical needs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review